Falgunee K Parekh

Learn More
BACKGROUND A vaccine to prevent infection and disease caused by Plasmodium vivax is needed both to reduce the morbidity caused by this parasite and as a key component in efforts to eradicate malaria worldwide. Vivax malaria protein 1 (VMP001), a novel chimeric protein that incorporates the amino- and carboxy- terminal regions of the circumsporozoite protein(More)
Vaccines have proven to be one of the most successful and efficient means of controlling infectious diseases of public health importance, including smallpox, polio, pertussis, and measles (1). The annual global burden of 300 –500 million new malaria cases and 1–3 million malaria-related deaths demonstrates the potential public health and socioeconomic(More)
  • 1